Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs AZD 7325 (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- Acronyms FAST-AS
- 21 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 25 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 25 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.